Kairos Pharma, Ltd.
Cash Flow Statement
| Line Item | Jun 2024 | Mar 2024 |
|---|---|---|
| Operating Activities | ||
| Net Income | $-253.0K | $-323.0K |
| Depreciation & Amortization | — | — |
| Depreciation | — | — |
| Amortization | $40.0K | $40.0K |
| Stock-Based Compensation | — | — |
| Net Cash from Operating Activities | $-168.0K | $36.0K |
| Investing Activities | ||
| Capital Expenditures | — | — |
| Business Acquisitions | — | — |
| Net Cash from Investing Activities | — | — |
| Financing Activities | ||
| Dividends Paid | — | — |
| Stock Repurchases | — | — |
| Net Cash from Financing Activities | $149.0K | $-89.0K |
| Net Change in Cash | $-19.0K | $-53.0K |
| Free Cash Flow | — | — |